Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults

References

• James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1789–1858. doi: 10.1016/S0140-6736(18)32279-7
   PubMed Web of Science ®Google Scholar
• Schizophrenia Global Prevalence [Internet]. [cited 2023 Nov 21]. Available from: https://www.who.int/news-room/fact-sheets/detail/schizophrenia
   Google Scholar
• Galletly C, Castle D, Dark F, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410–472. doi: 10.1177/0004867416641195
   PubMed Web of Science ®Google Scholar
• Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia. AJP. 2020;177(9):868–872. doi: 10.1176/appi.ajp.2020.177901
   Google Scholar
• National Collaborating Centre for Mental Health (UK). Psychosis and schizophrenia in adults: treatment and management: updated edition 2014 [internet]. London: National Institute for Health and Care Excellence (UK); 2014 [cited 2023 Nov 19]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK248060/
   Google Scholar
• Kim J, Ozzoude M, Nakajima S, et al. Insight and medication adherence in schizophrenia: an analysis of the CATIE trial. Neuropharmacology. 2020;168:107634. doi: 10.1016/j.neuropharm.2019.05.011
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962. doi: 10.1016/S0140-6736(13)60733-3
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21(3):419–429. doi: 10.1093/schbul/21.3.419
   PubMed Web of Science ®Google Scholar
• Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(Suppl 3):1–24. doi: 10.4088/JCP.15032su1
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Tanskanen A, Taipale H. 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. AJP. 2018;175(8):765–773. doi: 10.1176/appi.ajp.2018.17091001
   Google Scholar
• Torniainen M, Mittendorfer-Rutz E, Tanskanen A, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull. 2015;41(3):656–663. doi: 10.1093/schbul/sbu164
   PubMed Web of Science ®Google Scholar
• Vermeulen J, Van Rooijen G, Doedens P, et al. Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis. Psychol Med. 2017;47(13):2217–2228. doi: 10.1017/S0033291717000873
   PubMed Web of Science ®Google Scholar
• Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39–59. doi: 10.1007/s40263-020-00779-5
   PubMed Web of Science ®Google Scholar
• Greene M, Yan T, Chang E, et al. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21(2):127–134. doi: 10.1080/13696998.2017.1379412
   PubMed Web of Science ®Google Scholar
• Najarian D, Sanga P, Wang S, et al. A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia. Int J Neuropsychopharmacol. 2022;25(3):238–251. doi: 10.1093/ijnp/pyab071
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. doi: 10.1016/S0140-6736(19)31135-3
   PubMed Web of Science ®Google Scholar
• Naber D, Lambert M The CATIE and CUtLASS studies in schizophrenia: results and implications for Clinicians. CNS Drugs [Internet]. 2009 [cited 2023 Nov 19];PAP. Available from: doi: 10.2165/00023210-200923080-00002
   Google Scholar
• Carnovale C, Lucenteforte E, Battini V, et al. Association between the glyco-metabolic adverse effects of antipsychotic drugs and their chemical and pharmacological profile: a network meta-analysis and regression. Psychol Med. 2022;52(15):3508–3520. doi: 10.1017/S0033291721000180
   Web of Science ®Google Scholar
• Carnovale C, Battini V, Santoro C, et al. Umbrella review: association between antipsychotic drugs and metabolic syndrome hallmarks in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2023;63(3):S313–335. doi: 10.1016/j.jaac.2023.04.018
   PubMedGoogle Scholar
• Gründer G, Heinze M, Cordes J, et al. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. Lancet Psychiatry. 2016;3(8):717–729. doi: 10.1016/S2215-0366(16)00085-7
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Agarwal V, Kishi T, et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. 2013;18(1):53–66. doi: 10.1038/mp.2011.143
   PubMed Web of Science ®Google Scholar
• O’Brien A. Comparing the risk of tardive dyskinesia in older adults with first‐generation and second‐generation antipsychotics: a systematic review and meta‐analysis. Int J Geriat Psychiatry. 2016;31(7):683–693. doi: 10.1002/gps.4399
   PubMed Web of Science ®Google Scholar
• Zhang J-P, Gallego JA, Robinson DG, et al. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16(6):1205–1218. doi: 10.1017/S1461145712001277
   PubMed Web of Science ®Google Scholar
• Rossum I W-V, Weiser M, Galderisi S, et al. Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST). Lancet Psychiatry. 2023;10(3):197–208. doi: 10.1016/S2215-0366(23)00005-6
   PubMed Web of Science ®Google Scholar
• Boyer L, Falissard B, Nuss P, et al. Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders. Mol Psychiatry [Internet]. 2023 [cited 2023 Nov 19]; Available from: https://www.nature.com/articles/s41380-023-02175-z
   Google Scholar
• Mahlich J, Olbrich K, Wilk A, et al. Hospitalization rates and therapy costs of German schizophrenia patients who are initiated on long-acting injectable medication: a mirror-image study. Clin Drug Investig. 2020;40(4):355–375. doi: 10.1007/s40261-020-00900-y
   PubMed Web of Science ®Google Scholar
• Peitl V, Margetić BA, Vidrih B, et al. The impact of long-acting paliperidone in reducing hospitalizations and clinical severity in recent onset schizophrenia: a mirror-image study in real-world clinical setting. Clin Psychopharmacol Neurosci. 2022;20(1):118–125. doi: 10.9758/cpn.2022.20.1.118
   PubMed Web of Science ®Google Scholar
• Su K-P, Chang H-C, Tsai S-J, et al. Relapse and long-acting injectable risperidone: a 1-year mirror image study with a National Claims Database in Taiwan. Value Health. 2009;12:S118–S121. doi: 10.1111/j.1524-4733.2009.00643.x
   PubMed Web of Science ®Google Scholar
• Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274–280. doi: 10.1016/j.schres.2017.12.010
   PubMed Web of Science ®Google Scholar
• DerSarkissian M, Lefebvre P, Joshi K, et al. Health care resource utilization and costs associated with transitioning to 3-month paliperidone palmitate among US veterans. Clin Ther. 2018;40(9):1496–1508. doi: 10.1016/j.clinthera.2018.07.011
   PubMed Web of Science ®Google Scholar
• Lin D, Pilon D, Zhdanava M, et al. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate. Curr Med Res Opin. 2021;37(4):675–683. doi: 10.1080/03007995.2021.1882412
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Kim E, Bermak J, et al. Does half-life matter after antipsychotic discontinuation? A relapse comparison in schizophrenia with 3 different formulations of Paliperidone. J Clin Psychiatry. 2017 Jul;78(7):e813–820. doi: 10.4088/JCP.16m11308
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals Companies. Invega Sustenna (paliperidone palmitate) [prescribing information] [internet]. [cited 2022 Apr 23].
   Google Scholar
• Vats A, Nair AR, Bandhu AK, et al. Treatment of patients with schizophrenia and comorbid chronic hepatitis with paliperidone: a systematic review. Cureus [Internet]. 2023 [cited 2023 Nov 19]; Available from: https://www.cureus.com/articles/128339-treatment-of-patients-with-schizophrenia-and-comorbid-chronic-hepatitis-with-paliperidone-a-systematic-review
   Google Scholar
• Morris MT, Tarpada SP. Long-acting injectable paliperidone palmitate: a review of efficacy and safety. Psychopharmacol Bull. 2017;47:42–52.
   PubMedGoogle Scholar
• Schreiner A, Aadamsoo K, Altamura AC, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169(1–3):393–399. doi: 10.1016/j.schres.2015.08.015
   PubMed Web of Science ®Google Scholar
• Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review Board–blinded 15-month study. J Clin Psychiatry. 2015;76(5):554–561. doi: 10.4088/JCP.14m09584
   PubMed Web of Science ®Google Scholar
• Ravenstijn P, Remmerie B, Savitz A, et al. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3‐month formulation in patients with schizophrenia: a phase‐1, single‐dose, randomized, open‐label study. J Clin Pharma. 2016;56(3):330–339. doi: 10.1002/jcph.597
   PubMed Web of Science ®Google Scholar
• Bell Lynum KS, Turkoz I, Kim E. Paliperidone palmitate once‐every‐3‐months in adults with early illness schizophrenia. Early Intervention Psych. 2019;13(3):667–672. doi: 10.1111/eip.12685
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):830. doi: 10.1001/jamapsychiatry.2015.0241
   PubMed Web of Science ®Google Scholar
• Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. IJNPPY. 2016;19(7):yw018. doi: 10.1093/ijnp/pyw018
   Google Scholar
• Savitz AJ, Xu H, Gopal S, et al. Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study. Int Clin Psychopharmacol. 2017;32(6):329–336. doi: 10.1097/YIC.0000000000000190
   PubMed Web of Science ®Google Scholar
• Cirnigliaro G, Battini V, Cafaro R, et al. Barriers to the use of three-month paliperidone palmitate formulation: a study from an Italian real-world setting. Expert Rev Neurotherapeutics. 2023;23(11):1031–1039. doi: 10.1080/14737175.2023.2263650
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals Companies. Invega Trinza (paliperidone palmitate) [Prescribing Information] [Internet]. [cited 2022 Apr 23]. Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+TRINZA-pi.pdf.44
   Google Scholar
• Janssen Pharmaceuticals. Invega Hafyera (paliperidone palmitate) [prescribing information] [Internet]. [cited 2022 Apr 20]. Available from: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+HAFYERA-pi.pdf.46
   Google Scholar
• European Medicines Agency. Xeplion (paliperidone palmitate) [summary of product characteristics] [Internet]. [cited 2022 Apr 23]. Available from: https://www.ema.europa.eu/en/documents/product-information/xeplion-epar-productinformation_en.pdf.43
   Google Scholar
• European Medicines Agency. Trevicta (paliperidone palmitate) [summary of product characteristics] [Internet]. [cited 2022 Apr 23]. Available from: https://www.ema.europa.eu/en/documents/product-information/trevicta-epar-product-information_en.pdf.45
   Google Scholar
• European Medicines Agency. Byannli (paliperidone palmitate) [summary of product characteristics] [Internet]. [cited 2022 Apr 20]. Available from: https://www.ema.europa.eu/en/documents/product-information/byannli-previously-paliperidone-janssen-cilag-international-epar-product-information_en.pdf
   Google Scholar
• Højlund M, Correll CU. Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches. Expert Opin Pharmacother. 2023;24(13):1463–1489. doi: 10.1080/14656566.2023.2228686
   PubMed Web of Science ®Google Scholar
• Lisbeth P, Vincent H, Kristof M, et al. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol. 2016;72(2):175–184. doi: 10.1007/s00228-015-1965-1
   PubMed Web of Science ®Google Scholar
• Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in Humans. Drug Metab Dispos. 2008;36(4):769–779. doi: 10.1124/dmd.107.018275
   PubMed Web of Science ®Google Scholar
• Moons T, De Roo M, Claes S, et al. Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics. 2011;12(8):1193–1211. doi: 10.2217/pgs.11.55
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Spina E, Hiemke C, et al. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. Expert Rev Clin Pharmacol. 2018;11(12):1237–1253. doi: 10.1080/17512433.2018.1549489
   PubMed Web of Science ®Google Scholar
• Giron‐Hernandez C, Han JH, Alberio R, et al. Efficacy and safety of paliperidone palmitate 6-month versus paliperidone palmitate 3-month long-acting injectable in European patients with schizophrenia: a Post Hoc Analysis of a global phase-3 double-blind randomized non-inferiority study. NDT. 2023;Volume 19:895–906.
   Google Scholar
• Najarian D, Turkoz I, Knight RK, et al. Long-term efficacy and safety of paliperidone 6-month formulation: an open-label 2-year extension of a 1-year double-blind study in adult participants with schizophrenia. Int J Neuropsychopharmacol. 2023;26(8):537–544. doi: 10.1093/ijnp/pyad028
   PubMedGoogle Scholar
• FDA adverse event reporting system (FAERS) public dashboard | FDA [Internet]. [cited 2023 Nov 21]. Available from: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard
   Google Scholar
• European database of suspected adverse drug reaction reports [Internet]. [cited 2023 Nov 21]. Available from: https://www.adrreports.eu/en/index.html
   Google Scholar
• Carnovale C, Gringeri M, Battini V, et al. Beta‐blocker‐associated hypoglycaemia: new insights from a real‐world pharmacovigilance study. Brit J Clin Pharma. 2021;87(8):3320–3331. doi: 10.1111/bcp.14754
   PubMed Web of Science ®Google Scholar
• Bihan K, Lebrun-Vignes B, Funck-Brentano C, et al. Uses of pharmacovigilance databases: an overview. Therapie. 2020;75(6):591–598. doi: 10.1016/j.therap.2020.02.022
   PubMed Web of Science ®Google Scholar
• Research J, Development LA-D-B, Randomized, active-controlled, parallel-group study of paliperidone palmitate 6-month formulation. ClinicalTrials.Gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2024 Feb 28]. Available from: https://clinicaltrials.gov/study/NCT03345342NLMIdentifier:NCT03345342
   Google Scholar
• Janssen Research, Development LS-A, Open-label extension to a double-blind, randomized, active-controlled, parallel-group study of paliperidone palmitate 6-month formulation. ClinicalTrials.Gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2024 Feb 28]. Available from: https://clinicaltrials.gov/study/NCT04072575NLMIdentifier:NCT04072575
   Google Scholar
• BYANNLI Assesment report [Internet]. [cited 2023 Nov 21]. Available from: https://www.ema.europa.eu/en/documents/variation-report/byannli-h-c-5486-x-02-g-epar-assessment-report-variation_en.pdf
   Google Scholar
• Cicala G, De Filippis R, Barbieri MA, et al. Tolerability profile of paliperidone palmitate formulations: a pharmacovigilance analysis of the EUDRAVigilance database. Front Psychiatry. 2023;14:1130636. doi: 10.3389/fpsyt.2023.1130636
   PubMed Web of Science ®Google Scholar
• Peters L, Dyer M, Schroeder E, et al. Invega Hafyera (Paliperidone Palmitate): Extended-Release Injectable Suspension for Patients With Schizophrenia. J Pharm Technol. 2023;39(2):88–94. doi: 10.1177/87551225231153541
   PubMed Web of Science ®Google Scholar
• Milz R, Benson C, Knight K, et al. The effect of longer dosing intervals for long-acting injectable antipsychotics on outcomes in schizophrenia. Neuropsychiatr Dis Treat. 2023;19:531–545. doi: 10.2147/NDT.S395383
   PubMed Web of Science ®Google Scholar
• Hiemke C, Bergemann N, Clement H, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1/02):9–62. doi: 10.1055/s-0043-116492
   PubMed Web of Science ®Google Scholar